INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion Reports 2015 Fourth Quarter and Year-End Financial Results
Strong Balance Sheet to Support Planned 2016 Clinical Expansion of Complement Factor D Platform
View HTML
Toggle Summary Achillion to Present at Two Upcoming Investor Conferences
NEW HAVEN, Conn., March 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences: Cowen and Company 36 th Annual
View HTML
Toggle Summary Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference
NEW HAVEN, Conn., April 28, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 41 st Annual Health Care Conference on
View HTML
Toggle Summary Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs
-  Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 — -  Strong balance sheet to support planned 2016 clinical expansion of ACH-4471, Achillion's first small molecule
View HTML
Toggle Summary Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers - NEW HAVEN, Conn., May 19, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
View HTML
Toggle Summary Achillion to Present at Three Upcoming Investor Conferences
NEW HAVEN, Conn., June 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at three upcoming investor conferences: Jefferies 2016 Healthcare
View HTML
Toggle Summary Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
-  Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471  - -  Results support initiation of phase 1 multiple-ascending trial during the second quarter and phase 2 studies for paroxysmal nocturnal hemoglobinuria
View HTML
Toggle Summary Achillion Reports Second Quarter 2016 Financial Results
NEW HAVEN, Conn. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second quarter of 2016, Achillion reported a net loss of $18.5 million or $0.14 per share, compared with a
View HTML
Toggle Summary Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference
NEW HAVEN, Conn., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August
View HTML
Toggle Summary Achillion Announces Upcoming Presentation of Interim Phase 2a Results From the Janssen Sponsored Trial of Odalasvir, AL-335 and Simeprevir at the European Association for the Study of the Liver (EASL) Special Conference
ePoster presentation to detail study results including SVR12 for eight and six week triplet regimen and eight week doublet regimen
View HTML